Active substance
Atomoxetine
- SFDA 25
- US FDA 11
- Health Canada 57
- US price lines 7
- NHS prices 8
- Safety 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Acumen | 10 mg | Capsule, hard · Oral use | 28 Blister | SAR 160.75 | Generic · Prescription | ALTAIF PHARMACEUTICALS COMPANY | Valid |
| Acumen | 18 mg | Capsule, hard · Oral use | 28 Blister | SAR 160.75 | Generic · Prescription | ALTAIF PHARMACEUTICALS COMPANY | Valid |
| Acumen | 25 mg | Capsule, hard · Oral use | 28 Blister | SAR 160.75 | Generic · Prescription | ALTAIF PHARMACEUTICALS COMPANY | Valid |
| Acumen | 40 mg | Capsule, hard · Oral use | 28 Blister | SAR 160.75 | Generic · Prescription | ALTAIF PHARMACEUTICALS COMPANY | Valid |
| Acumen | 60 mg | Capsule, hard · Oral use | 28 Blister | SAR 160.75 | Generic · Prescription | ALTAIF PHARMACEUTICALS COMPANY | Valid |
| Attencare | 10 mg | Capsule, hard · Oral use | 30 Blister | SAR 190.85 | Generic · Prescription | Apex Pharma | Valid |
| Attencare | 18 mg | Capsule, hard · Oral use | 30 Blister | SAR 190.85 | Generic · Prescription | Apex Pharma | Valid |
| Attencare | 25 mg | Capsule, hard · Oral use | 30 Blister | SAR 190.85 | Generic · Prescription | Apex Pharma | Valid |
| Attencare | 40 mg | Capsule, hard · Oral use | 30 Blister | SAR 190.85 | Generic · Prescription | Apex Pharma | Valid |
| Attencare | 60 mg | Capsule, hard · Oral use | 30 Blister | SAR 190.85 | Generic · Prescription | Apex Pharma | Valid |
| Axepta | 10 mg | Capsule, hard · Oral use | 30 Blister | SAR 181.30 | Generic · Prescription | MS Pharma Saudi (MSPS) | Valid |
| Axepta | 18 mg | Capsule, hard · Oral use | 30 Blister | SAR 181.30 | Generic · Prescription | MS Pharma Saudi (MSPS) | Valid |
| Axepta | 25 mg | Capsule, hard · Oral use | 30 Blister | SAR 181.30 | Generic · Prescription | MS Pharma Saudi (MSPS) | Valid |
| Axepta | 40 mg | Capsule, hard · Oral use | 30 Blister | SAR 181.30 | Generic · Prescription | MS Pharma Saudi (MSPS) | Valid |
| Axepta | 60 mg | Capsule, hard · Oral use | 30 Blister | SAR 181.30 | Generic · Prescription | MS Pharma Saudi (MSPS) | Valid |
| STRATTERA 10MG CAPSULES | 10 mg | Capsule, hard · Oral use | 28 Blister | SAR 224.55 | NCE · Prescription | Lilly,S.A | Valid |
| STRATTERA 18MG CAPSULES | 18 mg | Capsule, hard · Oral use | 28 Blister | SAR 224.55 | NCE · Prescription | Lilly,S.A | Valid |
| STRATTERA 25MG CAPSULES | 25 mg | Capsule, hard · Oral use | 28 Blister | SAR 224.55 | NCE · Prescription | Lilly,S.A | Valid |
| STRATTERA 40MG CAPSULES | 40 mg | Capsule, hard · Oral use | 28 Blister | SAR 224.55 | NCE · Prescription | Lilly,S.A | Valid |
| STRATTERA 60MG CAPSULES | 60 mg | Capsule, hard · Oral use | 28 Blister | SAR 224.55 | NCE · Prescription | Lilly,S.A | Valid |
| STRATTERA 10MG CAPSULES | 10 mg | Capsule, hard · Oral use | 28 Blister | SAR 320.80 | NCE · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
| STRATTERA 18MG CAPSULES | 18 mg | Capsule, hard · Oral use | 28 Blister | SAR 320.80 | NCE · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
| STRATTERA 25MG CAPSULES | 25 mg | Capsule, hard · Oral use | 28 Blister | SAR 320.80 | NCE · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
| STRATTERA 40MG CAPSULES | 40 mg | Capsule, hard · Oral use | 28 Blister | SAR 320.80 | NCE · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
| STRATTERA 60MG CAPSULES | 60 mg | Capsule, hard · Oral use | 28 Blister | SAR 320.80 | NCE · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ATOMOXETINE HYDROCHLORIDE | EQ 18MG BASE; EQ 25MG BASE; EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE; EQ 100MG BASE; EQ 10MG BASE | capsule · oral | ZYDUS PHARMS USA INC | Prescription | 16 Sep 2010 |
| ATOMOXETINE HYDROCHLORIDE | EQ 10MG BASE; EQ 18MG BASE; EQ 25MG BASE; EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE; EQ 100MG BASE | capsule · oral | APOTEX | Prescription | 30 May 2017 |
| ATOMOXETINE HYDROCHLORIDE | EQ 10MG BASE; EQ 18MG BASE; EQ 25MG BASE; EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE; EQ 100MG BASE | capsule · oral | AUROBINDO PHARMA | Prescription | 30 May 2017 |
| ATOMOXETINE HYDROCHLORIDE | EQ 10MG BASE; EQ 18MG BASE; EQ 25MG BASE; EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE; EQ 100MG BASE | capsule · oral | GLENMARK PHARMS LTD | Prescription | 30 May 2017 |
| ATOMOXETINE HYDROCHLORIDE | EQ 10MG BASE; EQ 18MG BASE; EQ 25MG BASE; EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE; EQ 100MG BASE | capsule · oral | TEVA PHARMS USA | Prescription | 30 May 2017 |
| ATOMOXETINE HYDROCHLORIDE | EQ 10MG BASE; EQ 18MG BASE; EQ 25MG BASE; EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE; EQ 100MG BASE | capsule · oral | DR REDDYS | Prescription | 23 Feb 2018 |
| ATOMOXETINE HYDROCHLORIDE | EQ 10MG BASE; EQ 18MG BASE; EQ 25MG BASE; EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE; EQ 100MG BASE | capsule · oral | STRIDES PHARMA | Prescription | 18 Feb 2021 |
| ATOMOXETINE HYDROCHLORIDE | EQ 10MG BASE; EQ 18MG BASE; EQ 25MG BASE; EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE; EQ 100MG BASE | capsule · oral | HETERO LABS LTD V | Prescription | 11 Mar 2021 |
| ATONCY | EQ 4MG BASE/ML | solution · oral | MAP77 | Prescription | 20 Mar 2026 |
| ATOMOXETINE HYDROCHLORIDE | EQ 10MG BASE; EQ 18MG BASE; EQ 25MG BASE; EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE; EQ 100MG BASE | capsule · oral | PHARMAZONE | Prescription | 16 Jun 2026 |
| STRATTERA | EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 18MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 40MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 60MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 80MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule · oral | LILLY | Discontinued | 26 Nov 2002 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-ATOMOXETINE | 02318024 | 10 MG | CAPSULE · ORAL | APOTEX INC |
| APO-ATOMOXETINE | 02318032 | 18 MG | CAPSULE · ORAL | APOTEX INC |
| APO-ATOMOXETINE | 02318040 | 25 MG | CAPSULE · ORAL | APOTEX INC |
| APO-ATOMOXETINE | 02318059 | 40 MG | CAPSULE · ORAL | APOTEX INC |
| APO-ATOMOXETINE | 02318067 | 60 MG | CAPSULE · ORAL | APOTEX INC |
| APO-ATOMOXETINE | 02318075 | 80 MG | CAPSULE · ORAL | APOTEX INC |
| APO-ATOMOXETINE | 02318083 | 100 MG | CAPSULE · ORAL | APOTEX INC |
| ATOMOXETINE | 02445883 | 10 MG | CAPSULE · ORAL | SIVEM PHARMACEUTICALS ULC |
| ATOMOXETINE | 02445905 | 18 MG | CAPSULE · ORAL | SIVEM PHARMACEUTICALS ULC |
| ATOMOXETINE | 02445913 | 25 MG | CAPSULE · ORAL | SIVEM PHARMACEUTICALS ULC |
| ATOMOXETINE | 02445948 | 40 MG | CAPSULE · ORAL | SIVEM PHARMACEUTICALS ULC |
| ATOMOXETINE | 02445956 | 60 MG | CAPSULE · ORAL | SIVEM PHARMACEUTICALS ULC |
| ATOMOXETINE | 02467747 | 10 MG | CAPSULE · ORAL | SANIS HEALTH INC |
| ATOMOXETINE | 02467755 | 18 MG | CAPSULE · ORAL | SANIS HEALTH INC |
| ATOMOXETINE | 02467763 | 25 MG | CAPSULE · ORAL | SANIS HEALTH INC |
| ATOMOXETINE | 02467771 | 40 MG | CAPSULE · ORAL | SANIS HEALTH INC |
| ATOMOXETINE | 02467798 | 60 MG | CAPSULE · ORAL | SANIS HEALTH INC |
| ATOMOXETINE | 02467801 | 80 MG | CAPSULE · ORAL | SANIS HEALTH INC |
| ATOMOXETINE | 02467828 | 100 MG | CAPSULE · ORAL | SANIS HEALTH INC |
| AURO-ATOMOXETINE | 02471485 | 10 MG | CAPSULE · ORAL | AURO PHARMA INC |
| AURO-ATOMOXETINE | 02471493 | 18 MG | CAPSULE · ORAL | AURO PHARMA INC |
| AURO-ATOMOXETINE | 02471507 | 25 MG | CAPSULE · ORAL | AURO PHARMA INC |
| AURO-ATOMOXETINE | 02471515 | 40 MG | CAPSULE · ORAL | AURO PHARMA INC |
| AURO-ATOMOXETINE | 02471523 | 60 MG | CAPSULE · ORAL | AURO PHARMA INC |
| AURO-ATOMOXETINE | 02471531 | 80 MG | CAPSULE · ORAL | AURO PHARMA INC |
32 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ATOMOXETINE HCL 10 MG CAPSULE | $0.32216 | per EA | 23 Sep 2026 |
| US NADAC | ATOMOXETINE HCL 100 MG CAPSULE | $0.51448 | per EA | 23 Sep 2026 |
| US NADAC | ATOMOXETINE HCL 18 MG CAPSULE | $0.38181 | per EA | 23 Sep 2026 |
| US NADAC | ATOMOXETINE HCL 25 MG CAPSULE | $0.38297 | per EA | 23 Sep 2026 |
| US NADAC | ATOMOXETINE HCL 40 MG CAPSULE | $0.44218 | per EA | 23 Sep 2026 |
| US NADAC | ATOMOXETINE HCL 60 MG CAPSULE | $0.50934 | per EA | 23 Sep 2026 |
| US NADAC | ATOMOXETINE HCL 80 MG CAPSULE | $0.52256 | per EA | 30 Sep 2026 |
| NHS Drug Tariff | Atomoxetine 100mg capsules | £6.68 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Atomoxetine 10mg capsules | £11.73 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Atomoxetine 18mg capsules | £8.81 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Atomoxetine 25mg capsules | £10.94 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Atomoxetine 40mg capsules | £5.73 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Atomoxetine 4mg/ml oral solution sugar free | £35.33 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Atomoxetine 60mg capsules | £10.29 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Atomoxetine 80mg capsules | £11.82 | 28 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 29 Jun 2026 STRATTERA — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - MHRA 11 Dec 2014 Atomoxetine (Strattera▼): increases in blood pressure and heart rate
New contraindications, warnings, and advice for monitoring. - MHRA 11 Dec 2014 Atomoxetine: risk of psychotic or manic symptoms in children and adolescents
Atomoxetine is associated with treatment-emergent psychotic or manic symptoms in children and adolescents - consider stopping this if symptoms occur.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.